Claims for Patent: 10,166,290

Summary for Patent: 10,166,290

Title:	Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers
Abstract:	Inventor seeks patents related to the use in solid cancer patients of substances, (including, for example, dinitrohalogenated compounds) injected into tumor nodules in association with treatment with one or more checkpoint inhibitors that are administered before, during or after the intralesional (intratumoral) injection or injections.
Inventor(s):	Cohen; Max H. (Potomac, MD)
Assignee:
Application Number:	15/442,615
Patent Claims:	1. A method of treating a primary or recurrent cancerous nodule or nodules in a subject comprising administering an intralesional injection of compounds including dinitrohalogenated benzene in association with the use of previous, subsequent, or simultaneous administration of a checkpoint inhibitor selected from the group consisting of ipilimumab, pembrolizumab, nivolumab and tremelimumab. 2. The method of claim 1 wherein the dinitrohalogenated benzene is administered in a diluent or vehicle. 3. The method of claim 1 wherein the cancerous nodule is a solid tumor in cutaneous or non-cutaneous locations. 4. The method of claim 3 wherein the solid tumor is melanoma, breast cancer, squamous cancer, or non-small cell lung cancer. 5. The method of claim 1 wherein the dinitrohalogenated benzene is dinitrochlorobenzene or dinitrofluorobenzene. 6. The method of claim 1 wherein multiple intralesional agents including dinitrohalogenated benzene are injected. 7. The method of claim 1 wherein the cancerous nodule or nodules represent distant or local tumor. 8. A method of treating malignant nodules comprising co-administration of a checkpoint inhibitor selected from the group consisting of ipilimumab, pembrolizumab, nivolumab and tremelimumab either before, during or after administration of an intralesional injection of dinitrohalogenated benzene, wherein the most superficial area of the injected nodule becomes raised as the intralesional injection is administered. 9. The method of claim 1 wherein the subject does not have clinical, radiological or laboratory evidence of the spread of cancer beyond the adjacent regional lymph nodes consisting of the neck, axillary or groin nodes closest to the primary cancer site. 10. The method of claim 1 further comprising administering another intralesional compound or compounds. 11. The method of claim 2 wherein the diluent is acetone or olive oil.

Details for Patent 10,166,290

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2039-02-26
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2039-02-26
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2039-02-26